Once-daily topical treatment of target cutaneous neurofibromas (cNFs) with NFX‑179 Gel 1.5% achieved statistically significant reduction in size First randomized, double-blind, vehicle-controlled Phase 2b clinical trial to report positive results in the treatment of cutaneous…